Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial
JR Sims, JA Zimmer, CD Evans, M Lu, P Ardayfio… - Jama, 2023 - jamanetwork.com
Importance There are limited efficacious treatments for Alzheimer disease. Objective To
assess efficacy and adverse events of donanemab, an antibody designed to clear brain
amyloid plaque. Design, Setting, and Participants Multicenter (277 medical research
centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month
phase 3 trial that enrolled 1736 participants with early symptomatic Alzheimer disease (mild
cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology …
assess efficacy and adverse events of donanemab, an antibody designed to clear brain
amyloid plaque. Design, Setting, and Participants Multicenter (277 medical research
centers/hospitals in 8 countries), randomized, double-blind, placebo-controlled, 18-month
phase 3 trial that enrolled 1736 participants with early symptomatic Alzheimer disease (mild
cognitive impairment/mild dementia) with amyloid and low/medium or high tau pathology …